A partnership was reached by T2 Biosystems and Cidara Therapeutics to support trials for Cidara's echinocandin antifungal CD101s with the commercial placement of T2Dx instruments. The program will allow preferred sales terms to be offered by T2 to US trial sites, and reimbursement coverage to be provided by Cidara to centers that adopt T2Candida tests for patient enrollment.
T2 Biosystems enters partnership with Cidara
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.